NCT00767520 - Safety and Efficacy of Exemestane Plus Dasatinib Versus Placebo for Advanced ER+ Breast Cancer | Biotech Hunter

Enrollment

155

Participants

Timeline

Start Date

February 28, 2009

Primary Completion Date

March 31, 2011

Study Completion Date

December 31, 2012

Conditions

Breast Cancer

Interventions

DRUG

Exemestane + Dasatinib

Tablets, Oral, Exemestane 25 mg + Dasatinib 100 mg, once daily, until disease progression or unacceptable toxicity

DRUG

Exemestane + Placebo

Tablets, Oral, Exemestane 25 mg + Placebo 100 mg, once daily, until disease progression or unacceptable toxicity

Trial Locations (21)

24

Local Institution, Dublin

19106

Pennsylvania Oncology/Hematology Associates, Philadelphia

28033

Local Institution, Madrid

28041

Local Institution, Madrid

38120

The West Clinic, Memphis

59000

Local Institution, Lille

72189

Local Institution, Västerås

75651

Local Institution, Paris

92211

Local Institution, Saint-Cloud

92501

Compassionate Cancer Care Medical Group Inc, Riverside

92708

Compassionate Cancer Care Medical Group, Inc, Fountain Valley

500 05

Local Institution, Hradec Králové

150 06

Local Institution, Prague

80-462

Local Institution, Gdansk

80-952

Local Institution, Gdansk

93-509

Local Institution, Lodz

45-060

Local Institution, Opole

03186

Local Institution, Torrevieja

CM1 7ET

Local Institution, Chelmsford

NW1 2BU

Local Institution, London

CV22DX

Local Institution, Coventry